AI-Powered Clinical Trial Platform

One Platform.
Four Foundations.
Endless Possibilities.

From protocol creation to regulatory compliance, manage every aspect of clinical trial protocol development in one unified platform powered by AI.

Request DemoView Pricing
AGLAEAPHASE IIIPUBLISHED

REG-ONC-301

OncologyMetastatic Non-Small Cell Lung Cancer
prot-cvo7tudl43xo·Version 1.04·Fara Ashiru·Jan 15, 2026
Published ProtocolVersion 1.04
Comprehensive
75%Compliance
5,134Similar Trials
144Literature
19Guidelines
5Versions
Protocol Description
AI Generated

This comprehensive Phase III clinical trial evaluates the efficacy and safety of a novel combination immunotherapy regimen in patients with metastatic non-small cell lung cancer (NSCLC) who have progressed on prior platinum-based chemotherapy.

Study Objectives
AI Generated
Primary Objectives
  • Evaluate overall survival (OS) compared to standard of care
  • Assess progression-free survival (PFS) per RECIST 1.1
Secondary Objectives
  • Determine objective response rate (ORR)
  • Characterize safety and tolerability profile
Study Phase
Phase III
Target Enrollment
450 patients
Study Duration
48 months
Study Sites
75 sites globally
Target Population
AI Generated

Adults aged 18 years and older with histologically or cytologically confirmed metastatic non-small cell lung cancer (Stage IV) who have disease progression after platinum-based chemotherapy.

Key Inclusion Criteria
Age ≥18 years at time of informed consent
Histologically confirmed metastatic NSCLC (Stage IV)
ECOG Performance Status 0-1
Measurable disease per RECIST 1.1
Adequate organ function as defined by protocol
Key Exclusion Criteria
Prior treatment with PD-1/PD-L1 inhibitors
Active autoimmune disease requiring systemic treatment
Symptomatic CNS metastases
Known EGFR mutation or ALK rearrangement

Similar Clinical Trials

5,134Similar Trials
89%Avg. Similarity
12Sources
All Phases
Phase III
Completed
Recruiting
Search similar trials...
NCT0497138294% match
Phase III Study of Pembrolizumab Plus Chemotherapy in NSCLC
Phase IIICompleted
NCT0519563291% match
Nivolumab Combined with Ipilimumab in Advanced NSCLC
Phase IIIRecruiting
NCT0461359688% match
Atezolizumab vs Docetaxel in Previously Treated NSCLC
Phase IIICompleted
Greek Mythology Inspired

The Four Foundations

Named after the daughters of Asclepius, each module brings divine precision to clinical trial protocol development.

In Greek mythology, Panacea was the goddess of universal remedy—the cure-all. Her four siblings each represented a different aspect of healing: Aglaea (beauty & splendor), Hygeia (prevention), Iaso (recuperation), and Aceso (healing). Together, they formed complete healthcare. Panaceon AI embodies this philosophy—four essential tools that work together to create complete protocol excellence.

📝

AGLAEA

Protocol Generator

AI-powered protocol generation that creates FDA-ready drafts 30-40% faster. Aglaea, the Greek goddess of beauty and splendor, brings elegance and precision to every section of your clinical trial protocol.

✓ICH E6(R3) compliant structure
✓Section-by-section AI generation
✓Therapeutic area templates
✓Real-time collaboration
✓Export to Word/PDF
✓Version control & history
Learn More About AglaeaTry It Out
Protocol Generator — Study Objectives
✨ AI Generate
📄 Templates
💾 Save
✓ Study Information
✓ Study Timeline
◉ Study Objectives
○ Study Population
○ Interventions
○ Endpoints
Study ObjectivesAI Generated
✓

HYGEIA

Compliance Checker

Automated regulatory compliance analysis powered by AI. Hygeia, the Greek goddess of health and hygiene, ensures your protocols meet FDA, EMA, and ICH-GCP standards with 97% accuracy.

✓FDA, EMA, ICH-GCP validation
✓Real-time compliance scoring
✓Auto-fix suggestions
✓Regulatory citations
✓Issue severity categorization
✓Compliance history tracking
Learn More About HygeiaTry It Out
Compliance Checker — Protocol ABC-123
Compliance Analysis
94%
2
Critical
5
Warning
8
Info
✓
Study objectives clearly defined
ICH E6
!
Safety monitoring needs expansion
FDA 21
✓
Inclusion criteria complete
EMA
🔄

IASO

Amendment Tracker

AI identifies ripple effects and predicts downstream impacts of protocol amendments. Iaso, the Greek goddess of recovery, helps you manage changes without losing control.

✓Ripple effect detection
✓Version comparison & diff
✓Impact severity scoring
✓Regulatory document tracking
✓Change rationale capture
✓Amendment summary export
Learn More About IasoTry It Out
Amendment Tracker — Version History
Protocol ABC-123v3.2 Current
v1.0
v2.0
v3.0
v3.2
⚡ Ripple Effect — 4 sections affected
→ Section 3.1: Study Objectives
→ Section 5.2: Eligibility Criteria
→ Section 7.4: Statistical Analysis
→ Section 9.1: Safety Monitoring
🔍

ACESO

Knowledge Base

Semantic search across 500K+ clinical trials, FDA guidance, EMA guidelines, and scientific literature. Aceso, the Greek goddess of healing, brings knowledge to your fingertips.

✓500K+ clinical trials indexed
✓10+ regulatory data sources
✓Semantic AI search
✓PubMed & bioRxiv integration
✓Source filtering & relevance
✓Direct citation to protocols
Learn More About AcesoTry It Out
Knowledge Base — Search Results
🔍immunotherapy Phase III efficacy
All Sources
ClinicalTrials.gov
PubMed
FDA
CLINICALTRIALS.GOVNov 2025
Phase III Immunotherapy Study in NSCLC
A randomized, double-blind study evaluating...
PUBMEDOct 2025
Meta-Analysis: Checkpoint Inhibitors
Systematic review of 47 trials comparing...
FDA GUIDANCESep 2025
Immuno-Oncology Drug Development
Guidance for industry on clinical trial design...

Ready to Transform Your Protocols?

Start your 14-day free trial today. Full Professional features. No credit card required.

Request DemoView Pricing